UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 35

Sortiert nach

Next‐generation sequencing in salivary gland carcinoma: Targetable alterations lead to a therapeutic advantage—Multicenter experience

Head & neck, 2020-04, Vol.42 (4), p.599-607

2020

Volltextzugriff (PDF)

A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer

Investigational new drugs, 2022-04, Vol.40 (2), p.322-329

2022

Volltextzugriff (PDF)

Circulating microRNA-155-3p levels predicts response to first line immunotherapy in patients with metastatic renal cell carcinoma

Scientific reports, 2024-04, Vol.14 (1), p.8603-8603, Article 8603

2024

Volltextzugriff (PDF)

Circulating heparan sulfate chains and body weight contribute to anti-Xa levels in cancer patients using the prophylactic dose of enoxaparin

Journal of thrombosis and thrombolysis, 2020-07, Vol.50 (1), p.112-122

2020

Volltextzugriff (PDF)

Finding the optimal treatment sequence in metastatic castration-resistant prostate cancer—a narrative review

Translational andrology and urology, 2021-10, Vol.10 (10), p.3931-3945

2021

Volltextzugriff (PDF)

A generalizable machine learning framework for classifying DNA repair defects using ctDNA exomes

NPJ precision oncology, 2023-03, Vol.7 (1), p.27-27, Article 27

2023

Volltextzugriff (PDF)

412 First-in-human phase I/IIa trial to evaluate the safety and initial clinical activity of DuoBody®-PD-L1×4–1BB (GEN1046) in patients with advanced solid tumors

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A250-A251

2020

Volltextzugriff (PDF)

Glucocorticoids as an adjunct to oncologic treatment in solid malignancies – Not an innocent bystander

Critical reviews in oncology/hematology, 2018-06, Vol.126, p.37-44

2018

Volltextzugriff (PDF)

Circulating tumor DNA fraction (ctDNA%) to independently predict for clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.5049-5049

2021

Volltextzugriff (PDF)

First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors

Clinical cancer research, 2022-01, Vol.28 (1), p.57-70

2022

Volltextzugriff (PDF)

Machine-learning to predict utility of circulating tumor DNA (ctDNA) for somatic genotyping

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.232-232

2023

Volltextzugriff (PDF)

BMC128: A rationally designed live bacterial consortium for the potentiation of immune checkpoint therapy in solid tumors

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS2685-TPS2685

2022

Volltextzugriff (PDF)

A phase Ib, open-label, dose-escalation trial of naptumomab estafenatox (Nap) in combination with durvalumab (MEDI4736) in subjects with selected advanced or metastatic solid tumors

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.TPS3160-TPS3160

2020

Volltextzugriff (PDF)

Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors

Cancer discovery, 2022-05, Vol.12 (5), p.1248-1265

2022

Volltextzugriff (PDF)

Next-generation sequencing in thyroid cancers: do targetable alterations lead to a therapeutic advantage?: A multicenter experience

Medicine (Baltimore), 2021-06, Vol.100 (25), p.e26388-e26388

2021

Volltextzugriff (PDF)

Next Generation Sequencing in Salivary Gland Carcinomas: Do Actionable Mutations Lead to a Therapeutic Advantage? A Multicenter Experience

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e17582-e17582

2019

Volltextzugriff (PDF)

Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101)

Clinical cancer research, 2022-12, Vol.28 (23), p.5079-5087

2022

Volltextzugriff (PDF)

MO24-1 Phase I/IIa trial evaluating safety and clinical activity of DuoBody®-PD-L1×4-1BB (GEN1046) in advanced solid tumors

Annals of oncology, 2021-07, Vol.32, p.S313-S313

2021

Volltextzugriff (PDF)

Apalutamide for the treatment of metastatic castration-sensitive prostate cancer

Future oncology (London, England), 2020-12, Vol.16 (35), p.2905-2916

2020

Volltextzugriff (PDF)

Correction: First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors

Clinical cancer research, 2022-09, Vol.28 (18), p.4158-4158

2022

Volltextzugriff (PDF)

LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort

Journal of clinical oncology, 2021-01, Vol.39 (3_suppl), p.94-94

2021

Volltextzugriff (PDF)

Biallelic loss of TP53, PTEN, and RB1 in association to aggressive clinical features and poor outcomes in metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.5055-5055

2022

Volltextzugriff (PDF)

Correction: First-in-Class Anti-Immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors

Clinical cancer research, 2022-04, Vol.28 (8), p.1734-1734

2022

Volltextzugriff (PDF)

Anti–cytotoxic T-lymphocyte–associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2021-09, Vol.159, p.162-170

2021

Volltextzugriff (PDF)

Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase 2 LEAP-005 study

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.4080-4080

2021

Volltextzugriff (PDF)

1 – 25 von 35

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(34)
Mit Volltextzugriff
(33)

Publikationsform

Artikel
(35)

Sprache

Englisch
(35)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(14)
Life Sciences & Biomedicine
(13)
Humans
(9)
Oncology
(9)
Metastasis
(4)
Neoplasms - Drug Therapy
(4)
Immunotherapy
(3)
Male
(3)
Metastases
(3)
Patients
(3)
Prostate Cancer
(3)
Tumor Microenvironment
(3)
Androgens
(2)
Animals
(2)
Biomarkers
(2)
Cancer Therapies
(2)
Consent
(2)
Female
(2)
Hematology
(2)
High-Throughput Nucleotide Sequencing
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Next‐generation sequencing in salivary gland carcinoma: Targetable alterations lead to a therapeutic advantage—Multicenter experience

A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer

Circulating microRNA-155-3p levels predicts response to first line immunotherapy in patients with metastatic renal cell carcinoma

Circulating heparan sulfate chains and body weight contribute to anti-Xa levels in cancer patients using the prophylactic dose of enoxaparin

Finding the optimal treatment sequence in metastatic castration-resistant prostate cancer—a narrative review

A generalizable machine learning framework for classifying DNA repair defects using ctDNA exomes

412 First-in-human phase I/IIa trial to evaluate the safety and initial clinical activity of DuoBody®-PD-L1×4–1BB (GEN1046) in patients with advanced solid tumors

Glucocorticoids as an adjunct to oncologic treatment in solid malignancies – Not an innocent bystander

Circulating tumor DNA fraction (ctDNA%) to independently predict for clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors

Machine-learning to predict utility of circulating tumor DNA (ctDNA) for somatic genotyping

BMC128: A rationally designed live bacterial consortium for the potentiation of immune checkpoint therapy in solid tumors

A phase Ib, open-label, dose-escalation trial of naptumomab estafenatox (Nap) in combination with durvalumab (MEDI4736) in subjects with selected advanced or metastatic solid tumors

Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors

Next-generation sequencing in thyroid cancers: do targetable alterations lead to a therapeutic advantage?: A multicenter experience

Next Generation Sequencing in Salivary Gland Carcinomas: Do Actionable Mutations Lead to a Therapeutic Advantage? A Multicenter Experience

Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101)

MO24-1 Phase I/IIa trial evaluating safety and clinical activity of DuoBody®-PD-L1×4-1BB (GEN1046) in advanced solid tumors

Apalutamide for the treatment of metastatic castration-sensitive prostate cancer

Correction: First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors

LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort

Biallelic loss of TP53, PTEN, and RB1 in association to aggressive clinical features and poor outcomes in metastatic castration-resistant prostate cancer (mCRPC)

Correction: First-in-Class Anti-Immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors

Anti–cytotoxic T-lymphocyte–associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer

Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase 2 LEAP-005 study

Suchergebnisse filtern